Skip to content
lifestyle.sli.mg
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Teva Pharmaceutical Industries Ltd
Teva to Present at the Upcoming Investor Conferences in March
February 24, 2026
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
February 20, 2026
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
February 18, 2026
←
Previous Page
1
2
3